GSK’s two FDA approvals in one week, Roche’s $15 billion Hansoh bet, and the rise of point-of-care marketing — BigGo Finance
GSK had a week most drugmakers would trade a year for. On Monday, October 19, the FDA granted…
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest…
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week. Gilead…
Novartis’ ‘Relax Your Tight End’ wins Cannes Pharma Grand Prix
As a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around…
Gilead gives pink slips to 149, while Roche cuts 108 in Bay Area
Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round…
Top pharmaceutical companies for innovation: Roche, AbbVie, Novartis, and more
The 2020 Pharmaceutical Invention and Innovation Indices, compiled by IDEA Pharma, were generated prior to the unfolding COVID-19…
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Many cancer drugs work by blocking proteins associated with tumor progression, but there’s growing industry interest in drugs…